However, research is limited and results are mixed
Research supports spreading protein intake across three to four meals or feeding events, with each meal containing a sufficient dose (typically 2540 grams of high-quality protein) to maximally stimulate MPS. GLP-1 users face a practical problem: appetite suppression often compresses eating windows and reduces meal size, making it difficult to hit adequate per-meal protein doses even when overall daily targets are attempted
doi: 10.1006/abio.1999.4203 19 Gonzlez-MorenaJ
BPC 157 reduces nervous system inflammation and protects somatosensory neurons, suggesting it may do the same in the brain
Comparison with previous studies The SUSTAIN 9 (Semaglutide once weekly as add-on to SGLT-2i therapy in T2DM) and SURPASS-1 (Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist Tirzepatide in patients with type 2 diabetes) trials demonstrated that both SGLT2i and GLP-1RAs reduced HbA1c and body weight levels compared with placebo in patients with a history of medical treatment for diabetes ( Safety outcomes The SUSTAIN-9 trial demonstrated an association between SGLT2i use and genital and urinary tract infections ( Discrepancies in the SGLT2i or GLP-1RA type and dosage across studies may have influenced the results
Compared with EtOH-fed WT mice, KO mice were less susceptible to EtOH-induced deleterious effects, including body weight loss (reflected by less body weight gain), liver weight gain and hepatocyte damage (reflected by plasma ALT activity) (Table 1)
